Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study

NCT ID: NCT07177326

Last Updated: 2025-09-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 142 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2026-12-01

Brief Summary

Erectile dysfunction (ED) is characterized by the persistent inability to attain or sustain an erection adequate for satisfactory sexual intercourse. As one of the most common male sexual health disorders, ED exhibits a global prevalence of moderate-to-severe cases ranging between 5% and 20% (1). Although erectile dysfunction is not life-threatening, it can substantially impair both physical and psychosocial well-being, exerting a notable negative impact on the quality of life of affected individuals and their partners.

ED is a multifactorial condition associated with vascular, psychological, and, in some cases, idiopathic causes (2). Management strategies encompass lifestyle modification, pharmacotherapy particularly with phosphodiesterase type 5 (PDE5) inhibitors, vacuum erection devices, intracavernosal injections, and surgical options (1). ED frequently coexists with metabolic and cardiovascular disorders and shows a rising incidence with advancing age and the presence of cardiovascular risk factors (2). Both physiological and psychological mechanisms may underlie the condition; psychological etiologies tend to be more prevalent in younger, otherwise healthy individuals (3). The presence of preserved nocturnal erections is a key clinical indicator suggestive of a psychogenic origin of ED (4).

Phosphodiesterase-5 inhibitors (PDE5Is) represent the primary pharmacologic therapy for ED. Currently, seven PDE5Is (avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, udenafil, and vardenafil) are available in varying dosages and formulations. Their efficacy has been consistently demonstrated in randomized controlled trials (5)(6).

Sildenafil exhibits a rapid onset of action, typically beginning 30 minutes after administration, with an effective duration of 4 to 6 hours and a maximum pharmacological activity lasting up to 12 hours (7). While sildenafil is effective in managing erectile dysfunction, discontinuation rates among responders range from 20% to 50% (8). In contrast, tadalafil, a selective and long-acting PDE5 inhibitor introduced in 2003, has a slightly faster onset around 20 minutes and is recommended to be taken at least 30 minutes before sexual activity. Notably, tadalafil has the longest duration of action among PDE5 inhibitors, with effects lasting up to 72 hours. Approximately 52% of patients are able to achieve successful intercourse within 30 minutes of ingestion (9). The purpose of this study is to evaluate the efficacy and safety of Tadalafil 2.5 mg plus sildenafil 25 mg as a combination therapy versus tadalafil 5 mg monotherapy for Treatment of Erectile Dysfunction

Conditions

Erectile Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Group 1

patients recived Tadalafil 2.5 mg + Sildenafil 25 mg.

Group Type: ACTIVE_COMPARATOR

Tadalafil 2.5 mg

Intervention Type: DRUG

patients recived Tadalafil 2.5 mg daily

Sildenafil 25 mg

Intervention Type: DRUG

patients recived Sildenafil 25 mg daily

Group2

patients recived Tadalafil 5 mg monotherapy

Group Type: ACTIVE_COMPARATOR

Tadalafil 5 mg

Intervention Type: DRUG

patients recived Tadalafil 5 mg daily

Interventions

Tadalafil 2.5 mg

patients recived Tadalafil 2.5 mg daily

Intervention Type: DRUG

Sildenafil 25 mg

patients recived Sildenafil 25 mg daily

Intervention Type: DRUG

Tadalafil 5 mg

patients recived Tadalafil 5 mg daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• -Men aged 18-70 years with a clinical diagnosis of erectile dysfunction (ED) for ≥3 months.
• International Index of Erectile Function (IIEF-5) score ≤21.
• Stable sexual relationship for ≥3 months.
• Willingness to adhere to the study protocol and provide informed consent.
• No prior use of PDE5 inhibitors within 4 weeks before enrollment.

Exclusion Criteria

• -Severe cardiovascular disease (uncontrolled hypertension, recent MI/stroke).
• Hypersensitivity to tadalafil, sildenafil, or any PDE5 inhibitor.
• Severe hepatic/renal impairment (e.g., CrCl <30 mL/min, Child-Pugh C).
• Concomitant use of nitrates, strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole).
• History of priapism, penile deformities, or radical prostatectomy.
• Major psychiatric disorders affecting compliance.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Mohamed Mostafa Khedr

residant doctor at Assiut university hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

Tadal+Silden VSTadal ED

Identifier Type: -

Identifier Source: org_study_id